Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001827672-22-000008
Filing Date
2022-10-14
Accepted
2022-10-14 16:32:12
Documents
1
Period of Report
2022-10-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_166577950145627.html 4  
1 FORM 4 wf-form4_166577950145627.xml 4 6975
  Complete submission text file 0001827672-22-000008.txt   8332
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Azamian Bobak R. (Reporting) CIK: 0001827672 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 221311655